Navigation Links
ABR-Affinity BioReagents to Participate in the American Association for Cancer Research Meeting in San Diego, California, April 12 - 16, 2008
Date:4/11/2008

DENVER, and GOLDEN, Colo., April 11 /PRNewswire/ -- ABR-Affinity BioReagents, a leading global antibody manufacturer, announced today its continued support for the American Association for Cancer Research (AACR) and will exhibit at the annual meeting taking place at the San Diego Convention Center, April 12 - 16, 2008.

"The AACR meeting is a highlight of the year for ABR as we devote a significant portion of our corporate resources to supporting biological research in this critically important area," said Ken Wilczek, President of ABR-Affinity BioReagents. ABR's product portfolio includes over 3,000 quality guaranteed cancer biology antibodies. "Attendance at this meeting affords us the opportunity to enhance our understanding of what today's researchers are focusing on in terms of potential targets and timelines. Each year there are an increasing number of significant developments contributing to extraordinary advances in cancer-related disease research. This is just a great forum in which to interact on a personal level with a cross section of the top life science researchers in the U.S. and around the world. We derive much of our strategic direction from this type of input," finished Mr. Wilczek.

ABR-Affinity BioReagents will be launching 7,500 new products at the meeting across a selection of research areas including: Apoptosis; Cancer Biology; Heat Shock Protein; Ion Transport/Regulation; Neurobiology; Signal Transduction; Transcription Regulation; and Vision.

ABR will be located at booth #820 at next week's meeting in San Diego.

About ABR-Affinity BioReagents

Founded in 1989 with world headquarters in Golden, Colorado, ABR-Affinity BioReagents is a world leader in the manufacture and distribution of monoclonal and polyclonal antibodies, kits, recombinant proteins, siRNA, and custom antibody production services, known as Antibody on Demand(R).

With more than 35,000 antibodies focused in 43 research areas, ABR off
'/>"/>

SOURCE ABR-Affinity BioReagents
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. ABR-Affinity BioReagents Announces Agreements for U.S. Distribution of Research Antibodies
2. ABR-Affinity BioReagents to Exhibit at ASCB in Washington D.C., December 1 - 5, 2007
3. ABR-Affinity BioReagents Finalizes Agreement for Distribution of Osenses Antibodies in the U.S., Canada and Europe
4. ABR-Affinity BioReagents to Exhibit at the Society for Biomolecular Sciences in St. Louis, April 6 - 10, 2008
5. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
6. Boston Scientific to Participate in the Bear Stearns 20th Annual Healthcare Conference
7. China Medical Technologies to Participate in Credit Suisses 2007 Asian Technology Conference
8. Angiotech to participate in UBS Global Life Sciences Conference
9. Transcept Pharmaceuticals to Participate in Middle-of-the-Night (MOTN) Insomnia Investor Panel
10. Vicus Therapeutics Chief Executive Officer to Participate in BIOTECH 2007 Expert Panels
11. Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... ThermoFab, a US-based thermoforming company, has completed the delivery of ... sheet metal to a plastic enclosure with a smaller footprint ... ... Shirley, MA (PRWEB) December 14, 2009 -- ThermoFab, a US-based ... Flow Tester – helping Brookfield move from sheet metal to ...
(Date:12/11/2009)... Dendreon Corporation (Nasdaq: DNDN ) announced today ... offering have exercised in full their option to ... at the public offering price of $24.75 per ... the size of the offering to an aggregate ... expects to receive net proceeds from the offering ...
(Date:12/11/2009)... Boston College researchers have observed the "hot electron" effect ... successfully harvested the elusive charges using ultra-thin solar cells, ... the authors report in the current online edition of ... captured in solar cells, it generates free electrons in ... snare these charges, the electrons must reach the bottom ...
(Date:12/11/2009)... Calif., Dec. 11 Marrone Bio Innovations ... executive management team. Mr. Chris Hildreth joined MBI ... is responsible for expanding all commercial aspects of ... functions. Dr. Kin Sing (Ray) Lam joined MBI ... the company,s development efforts in scaling its broad ...
Breaking Biology Technology:Thermofab Helps Brookfield Engineering Move To A Compact Custom Plastic Enclosure 2Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 2Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 3Elusive 'hot' electrons captured in ultra-thin solar cells 2Marrone Bio Innovations Announces Two New Executive Appointments 2Marrone Bio Innovations Announces Two New Executive Appointments 3
... ... Final Approval, PRINCETON, N.J., June 25 ... tentative approval,from the U.S. Food and Drug Administration to manufacture and ... Tablets were $239 million (IMS - MAT: March 2008)., Ranbaxy ...
... and Decreased Expenses, CARY, N.C., June ... helping academic, healthcare and research-centric organizations realize,the ... BioMarin,Pharmaceutical Inc., a leading biopharmaceutical research and ... to streamline and,enhance procurement functions for its ...
... TraumaCure Inc. – makers of the ground-breaking hemostatic agent, WoundStat™ – ... 13485 certification for its quality system for design, development, production and ... WoundStat in August 2007 , ... BETHESDA, Md. ...
Other Biology Technology:Ranbaxy Gains Tentative Approval to Manufacture and Market Valganciclovir Hydrochloride Tablets 2SciQuest Announces Newest Life Sciences Customer; BioMarin Pharmaceutical Drives Spending Effectiveness with Automated, Intuitive Procurement 2 TraumaCure Receives Prestigious ISO 13485 Certification 2
(Date:12/11/2009)... granted an 18-month, exclusive option to startup Thermalin ... The company must reach certain milestones in order ... license on therapies designed to help patients with ... that it hopes will become an important part ... Insulin is a therapeutic protein used to manage ...
(Date:12/11/2009)... , Montreal, December 11, 2009 Canadian ... cancer. In the December 11 edition of the prestigious ... de Montral and the Universit de Sherbrooke explain how ... activity of cytokines, hormones that are culprits in cancer-prone ... people exposed to asbestos. , "Excessive cytokine activity ...
(Date:12/11/2009)... editor of the 4th edition of Springer,s classic reference ... given the Victor A. McKusick Leadership Award. The prize, ... of human genetics, was presented to him at the ... Genetics on 24 October 2009 in Honolulu, Hawaii. , ... at the University of Washington in Seattle. One of ...
Breaking Biology News(10 mins):Case Western Reserve University grants option to startup Thermalin Diabetes Inc. 2Scientists identify natural anti-cancer defenses 2Raptor Pharmaceutical Expands Board of Directors 5126 1Raptor Pharmaceutical Expands Board of Directors 5126 2Raptor Pharmaceutical Expands Board of Directors 5126 3Raptor Pharmaceutical Expands Board of Directors 5126 4Raptor Pharmaceutical Expands Board of Directors 5126 5Sanofi aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM 121 an Anti ErbB3 Monoclonal Antibody 5122 1Sanofi aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM 121 an Anti ErbB3 Monoclonal Antibody 5122 2Sanofi aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM 121 an Anti ErbB3 Monoclonal Antibody 5122 3Sanofi aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM 121 an Anti ErbB3 Monoclonal Antibody 5122 4Sanofi aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM 121 an Anti ErbB3 Monoclonal Antibody 5122 5Sanofi aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM 121 an Anti ErbB3 Monoclonal Antibody 5122 6Sanofi aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM 121 an Anti ErbB3 Monoclonal Antibody 5122 7Sanofi aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM 121 an Anti ErbB3 Monoclonal Antibody 5122 8Sanofi aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM 121 an Anti ErbB3 Monoclonal Antibody 5122 9MSN Introduces Online Tools to Help People Make Smarter Health and Lifestyle Decisions 58629 1MSN Introduces Online Tools to Help People Make Smarter Health and Lifestyle Decisions 58629 2MSN Introduces Online Tools to Help People Make Smarter Health and Lifestyle Decisions 58629 3
... sulfate supplementation before preterm delivery cuts the risk for ... by University of Alabama at Birmingham (UAB) obstetrician Dwight ... of The New England Journal of Medicine. , ... affecting control of movement and posture and limiting activity. ...
... management agencies are proud to announce the First Southern ... the Visalia Convention Center, from 9:00 a.m. - 5:30 ... of Change Affecting the Southern Sierra Ecosystems." This ... be an outstanding educational and networking opportunity., The science ...
... will receive a special discretionary prize, as part of ... Sciences. The European Molecular Biology Organization (EMBO) awards the ... outstanding communication with the public. The additional award was ... on a single organism using all available media. ...
Other Biology News:Common treatment to delay labor decreases preterm infants' risk for cerebral palsy 2Common treatment to delay labor decreases preterm infants' risk for cerebral palsy 3Southern Sierra Science Symposium planned for Visalia 2Southern Sierra Science Symposium planned for Visalia 3Southern Sierra Science Symposium planned for Visalia 4Southern Sierra Science Symposium planned for Visalia 5Southern Sierra Science Symposium planned for Visalia 6Southern Sierra Science Symposium planned for Visalia 7Southern Sierra Science Symposium planned for Visalia 8EMBO recognizes German zoologist for public communication 2
... This CLS number is a new product ... number. If showing no availability yet, please ... or contact customer service for assistance. ... Comp Dim: D H 100 ...
BD BioCoat BD MatrigelTM Matrix 100 mm Culture Dishes for hepatocytes, tissue-culture treated polystyrene with a uniform application of MATRIGEL Matrix....
...
... 5-OxoETE-d7 is used as an internal standard ... isotope dilution mass spectrometry. 5-OxoETE is a ... of 5-HETE in human neutrophils. It stimulates ... EC50 of 2 nM. 5-OxoETE selectively stimulates ...
Biology Products: